Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Anti‐CD52 mAb maintenance therapy vs observation Grade 3/4 adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Treatment‐related mortality – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Treatment discontinuation – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation All adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory drug maintenance therapy vs placebo/observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Quality of life · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) vs no treatment/lanolin Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Adherence · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
High‐pressure garment therapy vs low‐pressure garment therapy Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
High‐pressure garment therapy vs low‐pressure garment therapy Pain · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
High‐pressure garment therapy vs low‐pressure garment therapy Pruritus · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
High‐pressure garment therapy vs low‐pressure garment therapy Quality of life · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Different types of pressure garment (Caroskin Tricot plus an adhesive silicone gel sheet vs Gecko Nanoplast (silicone gel bandage)) Scar improvement (VSS) (0–13, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Different types of pressure garment (Caroskin Tricot plus an adhesive silicone gel sheet vs Gecko Nanoplast (silicone gel bandage)) Quality of life · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Different types of pressure garment (Caroskin Tricot plus an adhesive silicone gel sheet vs Gecko Nanoplast (silicone gel bandage)) Adherence · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) vs no treatment/lanolin Quality of life · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) vs no treatment/lanolin Adherence · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Disease‐related complications · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs preoperative pharmacological therapy and surgery All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs preoperative pharmacological therapy and surgery Health‐related quality of life · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Disease recurrence · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Surgery for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Non‐surgical therapy for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo QoL of participants living with SCD and their caregivers · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Adverse effects · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Frequency of hospitalization · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
L‐arginine vs placebo QoL of participants living with SCD and their caregivers · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
L‐arginine vs placebo Frequency of sickle cell‐related complications · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Frequency of crisis · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Vitamin C 1400 mg plus vitamin E 800 mg vs placebo QoL of participants living with SCD and their caregivers · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD) Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Severity of pain · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo QoL of participants living with SCD and their caregivers · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Frequency of hospitalization · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 vs placebo Frequency of sickle cell‐related complications · sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Vitamin C 1400 mg plus vitamin E 800 mg vs placebo Frequency of hospitalization · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD) Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Severity of pain · children and adults with sickle cell disease Antioxidant supplementation for sickle cell disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Escitalopram vs placebo Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Escitalopram vs placebo Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Overall survival · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |